Published in Cancer Res on June 01, 1991
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer (2011) 2.87
Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer (2000) 2.12
A high incidence of vertebral fracture in women with breast cancer. Br J Cancer (1999) 1.74
Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol (2011) 1.66
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
Parathyroid hormone related protein and hypercalcaemia in breast cancer. BMJ (1991) 1.41
TGF-β signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia (2011) 1.28
Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res (2010) 1.21
Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3 and TGF-β receptor type II. Biomaterials (2015) 1.15
Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res (2012) 1.14
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12
The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep (2012) 1.06
Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One (2010) 1.03
Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer (1995) 1.02
Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer (2003) 1.01
Physiopathology of spine metastasis. Int J Surg Oncol (2011) 1.00
The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer (2003) 1.00
Epidermal growth factor signalling and bone metastasis. Br J Cancer (2009) 0.98
Parathyroid hormone-related protein and ezrin are up-regulated in human lung cancer bone metastases. Clin Exp Metastasis (2007) 0.95
Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells. Biochem J (2003) 0.95
Cancer-associated bone disease. Osteoporos Int (2013) 0.94
A new human breast cancer cell line, KPL-3C, secretes parathyroid hormone-related protein and produces tumours associated with microcalcifications in nude mice. Br J Cancer (1996) 0.93
MicroRNAs in the control of metastatic bone disease. Trends Endocrinol Metab (2014) 0.92
PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br J Cancer (1997) 0.91
The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol (2012) 0.89
The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil"? Int J Breast Cancer (2011) 0.89
Bone structural components regulating sites of tumor metastasis. Curr Osteoporos Rep (2011) 0.88
Identification of PTHrP(12-48) as a plasma biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomarkers Prev (2013) 0.87
Manipulating the environment of cancer cells in bone: a novel therapeutic approach. J Clin Invest (2002) 0.86
Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer Microenviron (2011) 0.85
Human breast cancer cell metastasis to long bone and soft organs of nude mice: a quantitative assay. Clin Exp Metastasis (1997) 0.85
Notch3 is important for TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1. Cancer Gene Ther (2014) 0.84
Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients. Exp Ther Med (2012) 0.84
Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer (2002) 0.83
Parathyroid hormone-related protein specifies the mammary mesenchyme and regulates embryonic mammary development. J Mammary Gland Biol Neoplasia (2013) 0.83
Molecular alterations that drive breast cancer metastasis to bone. Bonekey Rep (2015) 0.83
Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.83
The role of the calcium-sensing receptor in bone biology and pathophysiology. Curr Pharm Biotechnol (2009) 0.82
Structural basis for antibody discrimination between two hormones that recognize the parathyroid hormone receptor. J Biol Chem (2009) 0.81
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
PTHrP increases transcriptional activity of the integrin subunit alpha5. Br J Cancer (2007) 0.80
Parathyroid hormone related protein in oral squamous cell carcinomas invading the mandible. J Clin Pathol (1995) 0.80
Expression of parathyroidlike protein in normal, proliferative, and neoplastic human breast tissues. Am J Pathol (1993) 0.79
Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer. J Cancer Res Clin Oncol (1997) 0.78
Immunohistochemical localization of parathyroid hormone-related protein (PTHrP) and serum PTHrP in normocalcemic patients with oral squamous cell carcinoma. Odontology (2005) 0.78
At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone. Odontology (2012) 0.78
Parathyroid Hormone-related Protein in Breast Cancer Tissues: Relationship between Primary and Metastatic Sites. Breast Cancer (1994) 0.78
Clues from hypercalcaemia. Br J Cancer (2002) 0.77
PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL. PLoS One (2013) 0.76
Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics. Transl Androl Urol (2015) 0.76
Parathyroid hormone-related protein secretion is inhibited by oestradiol and stimulated by antioestrogens in KPL-3C human breast cancer cells. Br J Cancer (1997) 0.75
Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases. Patient Prefer Adherence (2015) 0.75
Parathyroid hormone-related protein, bone metastases and hypercalcaemia of malignancy. Ann R Coll Surg Engl (1996) 0.75
Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis. Endocrinology (2016) 0.75
Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer (2017) 0.75
What Is Breast in the Bone? Int J Mol Sci (2016) 0.75
Implications of Hypoxia in Breast Cancer Metastasis to Bone. Int J Mol Sci (2016) 0.75
PTHrP inhibits BMP-6 expression through the PKA signaling pathway in breast cancer cells. J Cancer Res Clin Oncol (2010) 0.75
Is there an association between high heparanase level and osteoporosis risk in breast cancer patients without clinical evidence of bone metastases? Osteoporos Int (2005) 0.75
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Therapeutic approaches to bone diseases. Science (2000) 5.60
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A (1990) 4.40
Osteoblastic cells are involved in osteoclast formation. Endocrinology (1988) 4.37
Modulation of osteoclast differentiation. Endocr Rev (1992) 4.27
Role of osteoblasts in hormonal control of bone resorption--a hypothesis. Calcif Tissue Int (1981) 3.77
The relation of sensation in the anal canal to the functional anal sphincter: a possible factor in anal continence. Gut (1963) 3.33
A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis (1999) 2.93
Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol (1997) 2.88
Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun (1995) 2.87
Mycobacterium ulcerans in wild animals. Rev Sci Tech (2001) 2.84
The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology (1989) 2.83
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J Clin Microbiol (2000) 2.43
Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone (2002) 2.40
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Surgical significance of the bile duct of Luschka. Br J Surg (1989) 2.32
Multiple forms of nuclear deoxyribonucleic acid polymerases and their relationship with the soluble enzyme. Biochem J (1973) 2.32
Malignant glaucoma after laser iridotomy. Ophthalmology (1992) 2.28
Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun (1999) 2.28
Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis (1985) 2.21
The emergence of Mycobacterium ulcerans infection near Melbourne. Med J Aust (1996) 2.15
Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl Environ Microbiol (2000) 2.14
Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature (2000) 2.13
Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology (1999) 2.11
Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med (1999) 2.02
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology (2001) 1.98
A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. Proc Natl Acad Sci U S A (1995) 1.95
The changing role of the coroner. Can Med Assoc J (1978) 1.92
Ventricular arrhythmias caused by prenylamine. Br Med J (1977) 1.92
Induction of controlled hyperthermia in treatment of cancer. Lancet (1971) 1.91
A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect (1997) 1.82
Immune response to infection with Mycobacterium ulcerans. Infect Immun (2001) 1.82
Parathyroid hormone-related protein in hypercalcaemia associated with haematological malignancy. Br J Haematol (1996) 1.79
Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology (1998) 1.75
A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology (1998) 1.75
Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest (1986) 1.73
Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem (2005) 1.71
Regulation of alternative splicing by PTB and associated factors. Biochem Soc Trans (2005) 1.69
Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int (1999) 1.69
Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone (1999) 1.66
Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology (2001) 1.66
The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong Osteoporosis Study. J Bone Miner Res (1998) 1.65
Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol (1990) 1.63
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology (2000) 1.61
Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res (1990) 1.61
Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med (1995) 1.60
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest (1993) 1.58
Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res (1990) 1.54
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52
IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol (2001) 1.52
Detection and significance of occult metastases in node-negative breast cancer. Br J Surg (1993) 1.47
Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res (2001) 1.47
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet (1993) 1.45
Mycobacterium ulcerans infection on Phillip Island, Victoria. Med J Aust (1995) 1.42
Adenocarcinoma in situ of the uterine cervix progressing to invasive adenocarcinoma. Aust N Z J Obstet Gynaecol (1996) 1.39
Managing early breast cancer. Med J Aust (1995) 1.38
Calcitonin gene-related peptide stimulates cyclic AMP formation in rat aortic smooth muscle cells. Biochem Biophys Res Commun (1985) 1.38
Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res (1983) 1.38
Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum (2000) 1.37
Vesico-colic fistula complicating diverticular disease. Br J Urol (1969) 1.34
Presence of type III collagen in guinea-pig dermal scar. Biochem J (1976) 1.34
Structure of the 5' flanking region of the gene encoding human parathyroid-hormone-related protein (PTHrP). Gene (1989) 1.31
The histopathology of small vessels following microvascular repair. Br J Surg (1972) 1.30
Calcitonin receptor antibodies in the identification of osteoclasts. Bone (1999) 1.29
Functional properties of hormonally responsive cultured normal and malignant rat osteoblastic cells. Endocrinology (1981) 1.29
Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res (1989) 1.28
Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem (2001) 1.28
Mycobacterium ulcerans--a mini-review. J Med Microbiol (1999) 1.27
The donation process. Transplant Proc (1985) 1.27
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther (2007) 1.26
Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys (2000) 1.26
Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. J Bone Miner Res (2000) 1.25
Properties of a calcitonin receptor and adenylate cyclase in BEN cells, a human cancer cell line. Cancer Res (1980) 1.24
Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha. J Biol Chem (1999) 1.24
The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med (1996) 1.24
Insulin inhibition of protein degradation in cell monolayers. J Cell Physiol (1980) 1.23
1,25-dihydroxyvitamin-D-receptor in breast cancer cells. Lancet (1980) 1.22
Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci (2000) 1.22
Patient's assessment of the result of surgery for peptic ulcer. Lancet (1975) 1.22
Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone (2010) 1.21
Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol (1993) 1.18
Calcitonin. Curr Med Chem (1999) 1.18
Phosphaturic effect of thyrocalcitonin. Lancet (1966) 1.17
Parathyroid hormone-related protein and hypercalcemia. Cancer (1997) 1.17
PC8 [corrected], a new member of the convertase family. Biochem J (1996) 1.16
Regulation by calcitonin and glucocorticoids of calcitonin receptor gene expression in mouse osteoclasts. Endocrinology (1997) 1.16
Uric acid stone formation following ileostomy. Aust N Z J Surg (1966) 1.16